HK2 and neoplasm: A well-characterized HK2 inhibitor, 2-deoxy-D-glucose (2-DG), competitively inhibits HK2 by mimicking glucose, reducing glucose-6-phosphate (G6P) production and suppressing tumor growth in various preclinical models [20].